SB202190

0 reviews Write a review

Product Code: 3264
Availability: In Stock

$180.00

MG Options

Qty

SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.

Chemical Name:
4-(4-(4-fluorophenyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl)phenol

Biological Activity:
Biological Activity	SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo.
Technical Data:
M.W.	331.34
Formula:	C<sub>20</sub>H<sub>14</sub>N<sub>3</sub>OF
Solubility:	DMSO
Purity:	98%
Storage:	-20℃
CAS No:	152121-30-7
References:
References	Davies SP, et al. Biochem J, 2000, 351(Pt 1), 95-105. Nemoto S, et al. J Biol Chem, 1998, 273(26), 16415-16420. Chen W, et al. Oncogene, 2001, 20(29), 3921-3926. Prakash J, et al. J Pharmacol Exp Ther, 2006, 319(1), 8-19. Berkowitz P, et al. Proc Natl Acad Sci U S A, 2006, 103(34), 12855-12860. Muniyappa H, et al. Cell Signal, 2008, 20(4), 675-683. Hirosawa M, et al. Leuk Res, 2009, 33(5), 693-699. O'Sullivan AW, et al. J Surg Res, 2009, 152(1), 46-53. Paillas S, et al. Cancer Res, 2011, 71(3), 1041-1049. Tsai MS, et al. Mol Cancer Ther, 2012, 11(3), 561-571.

Write a review

Your Name

Your Review Note: HTML is not translated!

Rating Bad Good

Continue

SB202190

Write a review

About HDH PHARMA

Information

Extras

My Account